Date: 2013-10-08
Type of information: Product acquisition
Compound: GSK2336805 (GSK805)
Company: Janssen Pharmaceutical - J&J (USA) GSK (UK)
Therapeutic area: Infectious diseases
Type agreement: acquisition
Action mechanism: GSK2336805 is a HCV NS5A inhibitor.
Disease: chronic hepatitis C
Details: * On October 8, 2013, Medivir has announced that Janssen Pharmaceuticals, has acquired the investigational compound GSK2336805 (GSK805), an NS5a replication complex inhibitor in phase II development for the treatment of chronic hepatitis C. Janssen has acquired all rights to develop and commercialize GSK2336805 including in combination with other drugs. Janssen acquired the compound from an affiliate of GSK.
Janssen plans to initiate phase II studies to evaluate the use of GSK805 in interferon-free combinations with simeprevir (TMC435) and TMC647055, Janssen’s non-nucleoside polymerase inhibitor, for the treatment of chronic hepatitis C in adult patients with compensated liver disease.Simeprevir is a NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, for the treatment of genotype 1 and genotype 4 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells.
Financial terms: Financial details of the agreement have not been disclosed.
Latest news:
